43 related articles for article (PubMed ID: 31742732)
1. Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine.
Podichetty JT; Brinda BJ; Nelson RP; Karr AH; Prasad NK; Quinney S; Foxworthy Scott S; Kiel PJ
Pharmacotherapy; 2020 Jan; 40(1):26-32. PubMed ID: 31742732
[TBL] [Abstract][Full Text] [Related]
2. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.
Luznik L; Fuchs EJ
Immunol Res; 2010 Jul; 47(1-3):65-77. PubMed ID: 20066512
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients.
Piemontese S; Lupo Stanghellini MT; Sora F; Sica S; Peccatori J; Marcatti M; Metafuni E; Giammarco S; Greco R; Bruno A; Ciceri F; Bacigalupo A; Chiusolo P
Bone Marrow Transplant; 2024 May; 59(5):692-694. PubMed ID: 38355909
[No Abstract] [Full Text] [Related]
4. Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study.
Oostenbrink LVE; Von Asmuth EGJ; Jol-van der Zijde CM; Jansen-Hoogendijk AM; Vervat C; Bredius RGM; Van Tol MJD; Schilham MW; Sedlacek P; Ifversen M; Balduzzi A; Bader P; Peters C; Moes DJAR; Lankester AC
Haematologica; 2024 May; ():. PubMed ID: 38721739
[TBL] [Abstract][Full Text] [Related]
5. The effect of gastrointestinal graft-versus-host disease and diarrhea on the pharmacokinetic profile of sotrovimab in hematopoietic stem cell transplant recipients.
Boonyaratanakornkit J; Wang Q; Nader A; Kimball L; Stevens-Ayers T; Levkova M; Blazevic R; Nguyen J; Wright J; Castor J; Greninger AL; Ford E; Mielcarek M; Fordred S; Han J; Boeckh M; Waghmare A
J Infect Dis; 2024 May; ():. PubMed ID: 38743457
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Therapy in Older Adults With Hematologic Malignancies.
Mangan BL; DuMontier C; Hopkins JO; Abel GA; McCurdy SR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432220. PubMed ID: 38788182
[TBL] [Abstract][Full Text] [Related]
7. A cell culture system to model pharmacokinetics using adjustable-volume perfused mixing chambers.
Erickson P; Jetley G; Amin P; Mejevdiwala A; Patel A; Cheng K; Parekkadan B
Toxicol In Vitro; 2023 Sep; 91():105623. PubMed ID: 37236431
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socié G; Solano C; Vrhovac R; Zeiser R; Kröger N; Basak GW
Lancet Haematol; 2020 Feb; 7(2):e157-e167. PubMed ID: 32004485
[TBL] [Abstract][Full Text] [Related]
9. Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment.
DiMaggio E
Pharmacotherapy; 2020 Aug; 40(8):788-807. PubMed ID: 32530080
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis.
Lv X; Qi J; Zhou M; Shi B; Cai C; Tang Y; Pan T; Han Y
Crit Rev Oncol Hematol; 2020 Jun; 150():102944. PubMed ID: 32247246
[TBL] [Abstract][Full Text] [Related]
12. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease.
Yehudai-Ofir D; Henig I; Zuckerman T
Autoimmun Rev; 2020 Apr; 19(4):102493. PubMed ID: 32062034
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
[TBL] [Abstract][Full Text] [Related]
16. MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application.
Srinagesh HK; Ferrara JLM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101111. PubMed ID: 31779977
[TBL] [Abstract][Full Text] [Related]
17. Renal Complications after Hematopoietic Stem Cell Transplantation: Role of Graft-Versus-Host Disease in Renal Thrombotic Microangiopathy.
Mii A; Shimizu A; Yamaguchi H; Tsuruoka S
J Nippon Med Sch; 2020 Mar; 87(1):7-12. PubMed ID: 31776318
[TBL] [Abstract][Full Text] [Related]
18. Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - A meta analysis.
Geng C; Liu X; Chen M; Yang C; Han B
Leuk Res; 2020 Jan; 88():106266. PubMed ID: 31743865
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
